Lifecore Biomedical
LFCR | NASDAQ
$6.42
$0.00 (0.00%)
At close: Nov 16, 2026, 4:00 PM ET
$6.42
$0.00 (-0.08%)
After-hours:
Nov 16, 2026, 4:10 PM ET
Lifecore Biomedical Company Profile
Company profile explainedCompany Profile
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Key Executives
| Name | Position |
|---|---|
| Paul Josephs | President, Chief Executive Officer & Director |
| Ryan D. Lake | Executive Vice President & Chief Financial Officer |
| Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer |
| Jackie Q. Klecker | Executive Vice President of Quality & Development Services |
| Mark DaFonseca | Chief Commercial Officer |
| Parker K. Javid | Vice President |
| Thomas Guldager | Vice President of Operations |
| Thomas Salus | Chief Legal and Administration Officer & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | PREM14A | Filing |
| Oct 20, 2026 | 8-K | Current Report |
| Sep 29, 2026 | SC 13D/A | [Amend] Filing |
| Sep 29, 2026 | 8-K | Current Report |
| Sep 28, 2026 | SC 13D/A | [Amend] Filing |
| Sep 28, 2026 | DEFA14A | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 29, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Lifecore Biomedical
| Country | United States |
| IPO Date | Feb 15, 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 382 |
| CEO | Paul Josephs |
Contact Details
3515 Lyman Boulevard Chaska,
Minnesota 55318 United States
Stock Details
| Ticker Symbol | LFCR |
| Exchange | NASDAQ |
| Fiscal Year | June - May |
| Reporting Currency | USD |
| CIK Code | 0001005286 |
| CUSIP Number | 514766104 |
| ISIN Number | US5147661046 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove LFCR